 |
Pricing
California: “Ground Zero” for American Rx Price Controls
What are the chances that Rx price controls will actually take hold in the U.S. in the near future? Tom Norton believes the answer to that question can be summed up in one word: California
...Read more |
 |
Pricing
Turing's Shkreli Ruffles Feathers at Forbes Healthcare Summit
The All-Star CEO panel last week's Forbes Healthcare Summit was overshadowed by Matthew Herper's interview with industry's leading villain, Martin Shkreli, showing that drug pricing is still the leading topic on everyone's minds. Casey McDonald reports
...Read more |
 |
Forecast
Pharma and Biotech Financial Forecast: Mostly Sunny
The pharma and biotech business is coming off a strong year but headwinds persist—a clear product strategy, focused around a more demanding customer base, is the best way to ensure smooth sailing in 2016. Peter Young reports
...Read more |
In this paper, IMS Health describes the next generation of sales, marketing and technology – Orchestrated Customer Engagement (OCE). OCE seamlessly marshals the sequence, context, and purpose of messages to multiple influencing stakeholders.
 Learn more |
From the Editor
Demographic of Distress
A new discipline—population health—has emerged to contest disease treatment as an end in itself, looking at a larger set of behavioral and social factors to determine not just how people get sick, but why they stay well. The pregnant question is: besides advancing the science of medicine, what do biopharmaceuticals actually do to improve health overall?
...Read more |
Special Feature
Pharm Exec's Pipeline Report 2016
Will a drug pipeline harvest full of treatments founded on strong science, supportive regulation, and unmet medical need offer solace to shareholders and the promise of a reputational rebound? Will presidential politics add to the pressures on drug pricing, with a sour coda to the old refrain, “in the US, the market decides?” Casey McDonald reports
...Read more |
Patient-Centric Approach to Product Commercialization. In order for the patient to emerge center stage in a commercial approach, it's necessary for manufacturers to shift prioritization's to help the greatest number of patients gain access and remain on treatments. This requires aligning both R&D and marketing efforts with patient needs in order to drive positive outcomes– clinical as well as behavioral. The result is a successful product with far greater commercial value in a crowded and highly competitive market.
 Click here for more information |
 |
 //Nemucore Medical Innovations (Worcester, MA) appointed Dr. Michael V. Seiden to its Board of Directors and Clinical Advisory Board.
// Radius Health (Waltham, MA) announced the appointment of former GSK CEO Jean-Pierre (JP) Garnier to its Board of Directors and as Chair of the Compensation Committee.
// Lisa A. Miller joined Metabalon (Research Triangle Park, NC) as Vice President and General Manager of the company's Precision Medicine business.
// AgeneBio (Baltimore, MD) appointed Richard Mohs, PhD., as Vice President of Clinical Development. //
Immune Pharmaceuticals (New York, NY) appointed G. John Mohr as Senior Vice president of Business Development and as a member of the executive committee. //
|
|
|
|
|
